Application of anaerobic butyric acid bacteria in preparation of medicine for preventing and / or treating ventricular remodeling
By using anaerobic butyric acid bacteria to prevent and treat cardiac hypertrophy, myocardial hypertrophy and fibrosis, the prevention and treatment problems of heart failure are solved, the heart function is significantly improved, and effective methods for ventricular remodeling and heart failure are provided.
Patent Information
- Application Number
- CN202411122243.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art lacks effective methods for preventing and treating ventricular remodeling, resulting in a clinical lack of effective means for heart failure, especially when the energy metabolism of myocytes in the center of heart disease is affected, resulting in a decrease in cardiac diastolic and systolic function.
Anaerobic butyricum halli is used as a drug for the preparation of preventing and treating ventricular remodeling, and preventing and treating heart failure by preventing and treating cardiac hypertrophy, cardiac function decline, cardiac hypertrophy and myocardial fibrosis.
Anaerobic Butyric acid bacteria significantly improves cardiac hypertrophy, improves cardiac function, inhibits myocardial hypertrophy and fibrosis, effectively prevents and treats ventricular remodeling, and then prevents and treats heart failure, providing new treatment directions and methods.
Smart Images

Figure CN119033824A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to the use of anaerobic butyric acid bacteria (Anaerobutyricum hallii) in preparing a medicine for preventing and / or treating ventricular remodeling. Background Art
[0002] Ventricular remodeling refers to the changes in the size, shape, wall thickness, myocardial cells, collagen network, and vascular bed of the ventricles due to increased load or myocardial damage. Ventricular remodeling is a pathological and physiological reaction process secondary to lesion repair and overall ventricular compensation caused by various heart diseases such as chronic overload heart disease, chronic ischemic heart disease, myocardial infarction, and myocarditis. The severity of ventricular remodeling is closely related to the prognosis of heart disease and ultimately leads to heart failure and death. Therefore, blocking ventricular remodeling is an important link that cannot be ignored in preventing heart failure. Ventricular remodeling is the main pathological basis for the occurrence and development of heart failure and is a determining factor affecting morbidity and mortality.
[0003] Heart failure (HF) refers to a syndrome in which the heart's pumping function is impaired due to various factors (including coronary heart disease, hypertension, cardiomyopathy, etc.), and the cardiac output cannot meet the metabolic needs of systemic tissues. According to the "China Cardiovascular Health and Disease Report 2022", the current number of people suffering from cardiovascular diseases in my country is 330 million, of which 8.9 million suffer from heart failure, second only to stroke and coronary heart disease, and is on the rise. Studies have shown that sustained cardiac overload can cause structural and functional changes in the myocardium, including myocardial hypertrophy, fibrosis, cell hypertrophy, and inflammatory response, ultimately leading to cardiac remodeling. In this state, the energy metabolism of myocardial cells is also affected, resulting in a decrease in the diastolic and systolic function of the heart. At present, there is a lack of effective prevention and treatment methods for the progression from cardiac remodeling to heart failure in clinical practice. Therefore, it is of great theoretical and clinical significance to find specific biomarkers and biological pathways to improve cardiac function, prevent cardiac remodeling, and obtain effective treatments for heart failure.
[0004] The gut microbiome of patients with heart failure is characterized by an overall decrease in community diversity and a reduction in microorganisms with anti-inflammatory properties, while at the same time increasing potentially pathogenic microorganisms, the extent of colonization of which is correlated with the severity of heart failure. Second, certain heart failure-associated gut dysbiosis patterns are seen not only in other cardiovascular diseases (such as coronary artery disease), but also in other chronic diseases such as metabolic syndrome, type 2 diabetes, and inflammatory bowel disease, which have in common a chronic, low-grade, systemic inflammatory state. This means that future therapies developed that focus on the gut microbiome, targeting some of these shared gut microbial patterns, may be useful in more than one disease.
[0005] Therefore, there is currently no effective method for preventing and treating ventricular remodeling in clinical practice, and there is an urgent need to develop a treatment method that is beneficial to the intestinal ecology, safe, non-toxic and economical. Summary of the invention
[0006] The purpose of the present invention is to overcome the shortcomings of the prior art and provide the use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating ventricular remodeling.
[0007] The present invention finds through clinical cohort analysis that anaerobutyricum hallii is closely related to reducing the risk of death from coronary heart disease and improving cardiac function indicators. Aortic arch constriction (TAC)-induced mouse heart failure model test shows that Anaerobutyricum hallii has preventive and therapeutic effects on TAC-induced cardiac hypertrophy, decreased cardiac function, myocardial hypertrophy and myocardial fibrosis; isoproterenol (ISO)-induced primary cardiomyocyte heart failure cell model test shows that the metabolites of Anaerobutyricum hallii can inhibit the expression levels of β-MHC, a marker of myocardial hypertrophy, and ANP, a marker of heart failure, in primary cardiomyocytes. Therefore, Anaerobutyricum hallii has good preventive and / or therapeutic effects on heart failure and ventricular remodeling. At the same time, the present invention compares the effects of three strains of bacteria, namely, anaerobutyricum hallii, Roseburia intestinalis, and Faecalibacterium prausnitzii, on treating TAC-induced mouse heart failure model, among which Anaerobutyricum hallii has the best therapeutic effect.
[0008] To achieve the above object, the technical solution adopted by the present invention is:
[0009] In a first aspect, the present invention provides use of anaerobutyricum hallii in preparing a medicament for preventing and / or treating ventricular remodeling.
[0010] The present invention has found that anaerobutyricum hallii has preventive and therapeutic effects on TAC-induced cardiac hypertrophy, decreased cardiac function, myocardial hypertrophy and myocardial fibrosis, thereby effectively preventing and treating ventricular remodeling.
[0011] As a preferred embodiment of the use of the present invention, the anaerobic butyric acid bacteria (Anaerobutyricumhallii) prevents and / or treats heart failure by preventing and / or treating ventricular remodeling.
[0012] Ventricular remodeling is the main pathological basis of heart failure. Prevention and treatment of ventricular remodeling can inhibit the development of heart failure, thereby playing a role in preventing and treating heart failure.
[0013] As a preferred embodiment of the application of the present invention, the anaerobic butyric acid bacteria (Anaerobutyricumhallii) prevents and treats ventricular remodeling by inhibiting cardiac hypertrophy, decreased cardiac function, myocardial hypertrophy and myocardial fibrosis.
[0014] In a second aspect, the present invention provides use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating heart failure.
[0015] The present invention has found that anaerobutyricum hallii has preventive and therapeutic effects on TAC-induced cardiac hypertrophy, decreased cardiac function, myocardial hypertrophy and myocardial fibrosis, and can effectively prevent and treat heart failure.
[0016] In a third aspect, the present invention provides use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating cardiac hypertrophy.
[0017] In a fourth aspect, the present invention provides the use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating decreased cardiac function.
[0018] In a fifth aspect, the present invention provides use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating myocardial hypertrophy.
[0019] In a sixth aspect, the present invention provides the use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating myocardial fibrosis.
[0020] As a preferred embodiment of the application of the present invention, the anaerobic butyric acid bacteria (Anaerobutyricum hallii) is Anaerobutyricum hallii DSM 3353.
[0021] As a preferred embodiment of the application of the present invention, the anaerobic butyric acid bacteria (Anaerobutyricum hallii) includes the bacterial body of anaerobutyric acid bacteria (Anaerobutyricum hallii) or the culture solution of anaerobutyric acid bacteria (Anaerobutyricum hallii).
[0022] As a preferred embodiment of the application of the present invention, the culture solution of the anaerobic butyric acid bacteria (Anaerobutyricum hallii) is a sterile culture solution obtained after culturing the anaerobic butyric acid bacteria (Anaerobutyricum hallii).
[0023] As a preferred embodiment of the application of the present invention, the culture solution of the anaerobic butyric acid bacteria (Anaerobutyricum hallii) is a sterile culture solution obtained by culturing anaerobic conditions of anaerobic butyric acid bacteria (Anaerobutyricum hallii) using minced meat culture medium, centrifuging and filtering.
[0024] As a preferred embodiment of the application of the present invention, the effective dose of the anaerobic butyric acid bacteria (Anaerobutyricumhallii) is 1×10 8 CFU or above, and the effective intervention time is more than 28 days.
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] The present invention uses TAC to induce a mouse heart failure model for experiments, and the study found that anaerobutyricum hallii can significantly improve mouse cardiac hypertrophy, improve mouse cardiac function, inhibit myocardial hypertrophy, and reduce fibrosis. By preventing and / or treating decreased cardiac function, cardiac hypertrophy, myocardial hypertrophy, and myocardial fibrosis, the cardiovascular function and structure of mice develop in a good direction, thereby preventing and / or treating ventricular remodeling, and further preventing and / or treating heart failure. The present invention provides a new direction and method for the prevention and treatment of ventricular remodeling and heart failure. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 is the relationship between the quartile abundance of Anaerobutyricum hallii and the incidence of major adverse cardiovascular events (MACE) in Example 1 of the present invention;
[0028] Figure 2 The causal mediation analysis results of Anaerobutyricum hallii affecting clinical indicators through metabolites in Example 1 of the present invention;
[0029] Figure 3 The experimental results of Anaerobutyricum hallii in Example 2 of the present invention for preventing cardiac hypertrophy, wherein A is a mouse heart morphology diagram, B is the ratio of heart weight (HW) to body weight (BW), and C is the ratio of heart weight (HW) to tibia length (TL);
[0030] Figure 4 The experimental results of Anaerobutyricum hallii in Example 2 of the present invention for preventing cardiac function decline, wherein A is a representative ultrasound image of mouse heart, B is the left ventricular ejection fraction (LVEF) of mouse, C is the left ventricular fractional shortening (LVFS) of mouse, mean ± SEM, * indicates p < 0.01;
[0031] Figure 5 The experimental results of Anaerobutyricum hallii in preventing myocardial hypertrophy and inflammatory cell infiltration in Example 2 of the present invention, wherein A is a longitudinal section of a mouse heart, and B is a representative HE staining image;
[0032] Figure 6 The results of the effect of Anaerobutyricum hallii treatment on the food intake and body weight of TAC-induced heart failure mice in Example 2 of the present invention, wherein A represents the change in food intake and B represents the change in body weight;
[0033] Figure 7 The experimental results of Anaerobutyricum hallii for treating cardiac hypertrophy in Example 2 of the present invention, wherein A is a mouse heart morphology diagram, B is the ratio of heart weight (HW) to body weight (BW), and C is the ratio of heart weight (HW) to tibia length (TL);
[0034] Figure 8 The results of cardiac ejection fraction and short-axis shortening rate of mice after treatment with Anaerobutyricum hallii in Example 2 of the present invention, A is a representative ultrasound image of mouse heart, B is the left ventricular ejection fraction (LVEF) of mice, C is the left ventricular short-axis shortening rate (LVFS) of mice, mean±SEM, ** indicates p<0.01; *** indicates p<0.001;
[0035] Fig. 9The results of the left ventricular wall thickness and left ventricular volume of mice after treatment with Anaerobutyricum hallii in Example 2 of the present invention, wherein A is the left ventricular anterior wall thickness at end systole (LVAW; s) of the mouse, B is the left ventricular anterior wall thickness at end diastole (LVAW; d), C is the left ventricular posterior wall thickness at end systole (LVPW; s), D is the left ventricular posterior wall thickness at end diastole (LVPW; d), E is the left ventricular end systolic volume (LV vol; s), and F is the left ventricular end diastolic volume (LV vol; d);
[0036] Fig.10 The experimental results of Anaerobutyricum hallii improving myocardial hypertrophy and inflammatory cell infiltration in Example 2 of the present invention, wherein A is a cross-sectional view of a mouse heart, B is a representative view of HE staining of myocardial cells, and C is a representative view of inflammatory cell infiltration in cardiac tissue;
[0037] Fig.11 The results of the effect of Anaerobutyricum hallii treatment on cardiac tissue and perivascular fibrosis in Example 2 of the present invention, wherein A is the change of cardiac tissue fibrosis in mice, B is the change of perivascular fibrosis in mice, and C is the percentage of collagen deposition area (Collagen area / whole section);
[0038] Fig.12 The results of cardiac ejection fraction and short-axis shortening rate of mice after treatment with different bacteria in Example 3 of the present invention, A is the left ventricular ejection fraction (LVEF) of mice, B is the left ventricular short-axis shortening rate (LVFS) of mice, mean ± SEM, * indicates p < 0.01, ** indicates p < 0.01, *** indicates p < 0.001;
[0039] Fig.13 The results of the effects of the metabolites of Anaerobutyricum hallii on the expression of markers of heart failure and myocardial hypertrophy in primary cardiomyocytes in Example 4 of the present invention, A is a representative graph of protein expression of β-MHC and ANP, B is a statistical graph of the relative expression of β-MHC, and C is a statistical graph of the relative expression of ANP. DETAILED DESCRIPTION
[0040] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.
[0041] Unless otherwise specified, other materials, reagents, etc. used in the examples can be obtained from commercial sources.
[0042] Example 1 Predictive effect of Anaerobutyricum hallii on the risk of death in patients and analysis of its correlation with cardiac function indicators
[0043] The clinical data of 1,310 patients with coronary heart disease established by the research group of the present invention team (including cardiac function indicators, biochemical indicators, intestinal bacteria abundance, and survival status during follow-up) were used to study the predictive effect of anaerobutyricum hallii on the risk of death in the clinical cohort of patients with coronary heart disease and its correlation with cardiac function indicators. The correlation table between the key clinical data and Anaerobutyricum hallii in the coronary heart disease patient cohort is shown in Table 1 below, the demographic characteristics of the coronary heart disease patient cohort are shown in Table 2 below, and the intestinal microorganisms associated with MACE events in coronary heart disease are shown in Table 3 below (univariate Cox regression was used to analyze and compare the data). Preliminary analysis showed that there was a correlation between the presence of Anaerobutyricum hallii and the patient's cardiac function indicators.
[0044] Table 1
[0045]
[0046] Table 2
[0047]
[0048] Table 3
[0049]
[0050] 1. The correlation between the abundance of Anaerobutyricum hallii and clinical indicators: high-sensitive troponin-T (TNT_HS), pro-B-type natriuretic peptide (proBNP), and C-reactive protein (CRP) was analyzed by Spearman correlation, and the correlation between the abundance of Anaerobutyricum hallii and the incidence of heart failure (HF) was analyzed by logistic regression.
[0051] The Spearman correlation results are shown in Table 4 below.
[0052] Table 4
[0053] Valuation Standard error t-value P Anaerobutyricum hallii proBNP -0.116444 0.0267191 -4.358061 <![CDATA[1.42*10 -5 ]]> Anaerobutyricum hallii TNT_HS -0.093754 0.0274145 -3.419865 <![CDATA[6.462*10 -4 ]]> Anaerobutyricum hallii CRP -0.055838 0.0277643 -2.011156 0.0445179 Anaerobutyricum hallii HF -0.071619 0.0283043 -2.53031 0.0115211
[0054] The results in Table 4 showed that the abundance of Anaerobutyricum hallii was negatively correlated with the incidence of heart failure (HF), and was also negatively correlated with myocardial loss indicators (TNT_HS, proBNP) and inflammatory indicators (CRP).
[0055] 2. The Kaplan-Meier (KM) method was used to analyze the relationship between the quartile (Q1, Q2, Q3, Q4) abundance of Anaerobutyricum hallii and the incidence of major adverse cardiovascular events (MACE, including myocardial infarction, stroke, and death).
[0056] The relationship between the quartile abundance of Anaerobutyricum hallii and the incidence of major adverse cardiovascular events (MACE) Figure 1 As shown, the results showed that there was a significant association between the abundance of Anaerobutyricum hallii and the long-term incidence of major adverse cardiovascular events in patients, and a high abundance of Anaerobutyricum hallii was associated with a lower risk of MACE.
[0057] 3. Using R Studio program (version 4.5.0), the "mediation" R package was used to conduct causal mediation analysis of the mediating metabolites of Anaerobutyricum hallii affecting clinical indicators. It is mainly divided into the following two steps: 1) Establishing the model of the results (clinical indicators ~ Anaerobutyricum hallii) based on the out.fit function; 2) Establishing the model of the mediator (metabolites ~ Anaerobutyricum hallii) based on the med.fit function. The results output the average causal mediation effect (ACME), direct effect (ADE) and proportion of mediation effect.
[0058] The results of causal mediation analysis of the effects of Anaerobutyricum hallii on clinical indicators through metabolites are as follows Figure 2 The results showed that Anaerobutyricum hallii can mediate the changes of TNT_HS and proBNP through metabolites such as N-methyl-D-aspartic acid, protocatechuic aldehyde, D-(+)-malic acid, 3,3',5-triiodo-L-thyronine, 2-picolinic acid, and nicotinic acid.
[0059] The above results suggest that Anaerobutyricum hallii can serve as a useful biomarker in the prognosis assessment and management of patients with cardiovascular diseases such as coronary heart disease.
[0060] Example 2 Analysis of the preventive and therapeutic effects of anaerobutyricum hallii on heart failure and ventricular remodeling
[0061] 1. Isolation and cultivation of strain Anaerobutyricum hallii
[0062] Anaerobutyricum hallii was isolated from a stool sample of a healthy donor and identified as the known strain Anaerobutyricum hallii DSM 3353.
[0063] DSMZ Medium 110 (minced meat medium) was used for anaerobic culture at 37°C. Bacteria were cultured in suspension under anaerobic conditions and the density was adjusted to 5×10 9 CFU / mL. The cultured Anaerobutyricum hallii was separated and prepared into a bacterial suspension using sterile water for subsequent experiments.
[0064] 2. Experimental Animals
[0065] C57BL / 6J mice were purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd. and maintained at the Institute of Biological and Medical Engineering, Guangdong Academy of Sciences; experimental unit use license number: SYXK (Yue) 2023-0183). All operations in this study followed the Chinese Laboratory Animal Ethics and were approved by the Animal Ethics Committee of Guangdong Provincial People's Hospital.
[0066] 3. Construction of aortic arch constriction (TAC) mouse model
[0067] Adult male C57BL / 6J mice aged 10 weeks and weighing about 20-25g were selected. After anesthesia, fixation, hair removal, and skin preparation, the skin was cut from the upper edge of the suprasternal fossa and cut along the midline of the sternum to the second intercostal space (about 1 cm incision). After blunt separation of the fascia at the suprasternal fossa to expose the trachea, small curved forceps entered the suprasternal fossa and pushed the thymus tissue to both sides. A retractor was used to expose the visual field, and the front section of a homemade syringe needle (the front section was cut off and made into a right angle) was inserted into the blood vessels at the brachiocephalic trunk with a No. 6 line and pre-knotted. Then a 27G needle (made into a right angle) was padded and knotted. After ligation, the 27G needle was slowly removed, the muscle tissue was sutured, and the skin was sutured and placed in a warm environment for awakening, and the model was completed. The sham operation group was the same, only threading was done without ligation.
[0068] 4. Preventive Experiments
[0069] To evaluate the preventive effect of Anaerobutyricum hallii gavage on TAC-induced heart failure, some mice were given preventive Anaerobutyricum hallii gavage for 4 weeks before TAC surgery.
[0070] (1) Preventive experimental grouping
[0071] ① Normal control group (Sham): 4 C57BL / 6J mice, each mouse was gavaged with 0.2 mL of sterile water every day for 28 consecutive days (4 weeks);
[0072] ② Model control group (TAC): 4 C57BL / 6J mice, each mouse was gavaged with 0.2 mL of sterile water every day for 28 days (4 weeks), and then underwent TAC construction surgery;
[0073] ③Anaerobutyricum hallii experimental group (Hallii+TAC): 4 C57BL / 6J mice, each mouse was treated with 0.2 mL of 5×10 9 CFU / mL of Anaerobutyricum hallii suspension dissolved in sterile water (1×10 9 CFU) by intragastric administration for 28 consecutive days (4 weeks), and then TAC construction surgery was performed.
[0074] (2) Preventive experiments
[0075] 5-week-old C57BL / 6J mice, weighing 16-18g, were numbered in sequence after ear tags were punched in the inner side of the right ear with a hole puncher; constant temperature and humidity, 12h light cycle, free food and water, regular replacement of bedding; normal feed was adaptively fed for 1 week to 6 weeks of age and then treated according to experimental groups. After the end of gavage in the control group and after TAC construction surgery in the experimental group, the functional structure of the mouse heart was detected by ultrasound; after killing the mice, the body weight (BW) and tibia length (TL) of each group of mice were recorded, the mouse heart was removed, and the heart weight (HW) was recorded; and the heart was stained with HE. The activity, coat color and death of the mice were observed every day, and the weight of the mice was weighed regularly.
[0076] The results of the experiment on the prevention of cardiac hypertrophy by Anaerobutyricum hallii are as follows Figure 3 As shown, A is the mouse heart morphology, B is the ratio of heart weight (HW) to body weight (BW), and C is the ratio of heart weight (HW) to tibia length (TL). The results showed that oral administration of Anaerobutyricum hallii suspension can effectively inhibit TAC-induced cardiac hypertrophy and has the effect of preventing cardiac hypertrophy.
[0077] (3) Mouse heart function and structure detection
[0078] Ultrasound examinations and analysis of the mice were performed by ultrasound physicians who were unaware of the experimental group design. First, the ultrasound system parameters on the small animal ultrasound instrument were set in advance, and then the isoflurane and oxygen flow rates of the small animal anesthesia system were set to anesthetize the mice. An appropriate amount of depilatory agent was applied to the chest of the mouse, and then a thick ultrasonic coupling agent was applied to the depilated area for ultrasound detection. A 30MHz high-frequency linear array probe was placed on the left ventricular short-axis section at the level of the papillary muscle of the mouse, and two-dimensional ultrasound images and M-mode ultrasound images of at least 10 cardiac cycles were collected. The main parameters collected in this study included left ventricular ejection fraction (LVEF), left ventricular short-axis shortening rate (LVFS), left ventricular anterior wall thickness at end systole (LVAW; s), left ventricular anterior wall thickness at end diastole (LVAW; d), left ventricular posterior wall thickness at end systole (LVPW; s), left ventricular posterior wall thickness at end diastole (LVPW; d), left ventricular end systolic volume (LV vol; s), and left ventricular end diastolic volume (LV vol; d). The acquired images were statistically analyzed using the built-in ultrasound analysis system of the ultrasound instrument.
[0079] The results of the experiment on Anaerobutyricum hallii in preventing the decline of cardiac function are as follows Figure 4 As shown, A is a representative image of mouse cardiac ultrasound, B is the left ventricular ejection fraction (LVEF) of mice, C is the left ventricular fractional shortening (LVFS) of mice, mean±SEM, * indicates p<0.01. The results showed that oral administration of Anaerobutyricum hallii suspension can effectively inhibit the decline of cardiac function induced by TAC and has the effect of improving cardiac function.
[0080] (4) HE staining
[0081] The main steps are: baking at 55℃ for 30min→xylene for 5min, 3 times→100% alcohol for 1min→95% alcohol for 1min→70% alcohol for 1min→double distilled water for 1min→hematoxylin solution for 5min→washing with water for 1min→1% hydrochloric acid alcohol for 1-3s→washing with water for 1min→Scott solution for 1min→washing with water for 1min→eosin solution for 3-5min→washing with distilled water to remove floating color→70% alcohol for 1s→95% alcohol for 1s→100% alcohol for 30s, 3 times→xylene for 2min, 3 times→seal the slide immediately before xylene dries→dry in a fume hood and take pictures under a microscope. For each picture, select more than 3 cells with clear boundaries and nuclei roughly located in the center, and circle the cell area using Image-Pro Plus6.0 software.
[0082] The experimental results of Anaerobutyricum hallii in preventing myocardial hypertrophy and inflammatory cell infiltration are as follows Figure 5As shown, A is a longitudinal section of mouse heart, and B is a representative HE staining image. The results showed that oral administration of Anaerobutyricum hallii suspension can effectively inhibit TAC-induced cardiac hypertrophy, myocardial hypertrophy and inflammatory cell infiltration, and has the effect of preventing cardiac hypertrophy, myocardial hypertrophy and inflammatory cell infiltration.
[0083] In conclusion, Anaerobutyricum hallii can prevent ventricular remodeling and heart failure by inhibiting cardiac hypertrophy, decreased cardiac function, myocardial hypertrophy and inflammatory cell infiltration.
[0084] 5. Therapeutic experiments
[0085] To evaluate the therapeutic effect of Anaerobutyricum hallii gavage on TAC-induced heart failure, some mice were given Anaerobutyricum hallii therapeutic gavage for 6 weeks after TAC construction surgery.
[0086] (1) Therapeutic experimental groups
[0087] ① Normal control group (Sham): 8 C57BL / 6J mice, each mouse was gavaged with 0.2 mL of sterile water every day;
[0088] ② Model control group (TAC): 10 C57BL / 6J mice. After TAC construction surgery, each mouse was gavaged with 0.2 mL of sterile water every day;
[0089] ③Anaerobutyricum hallii experimental group (TAC+hallii): 10 C57BL / 6J mice. After TAC construction surgery, each mouse was treated with 0.2 mL of 5×10 9 CFU / mL of Anaerobutyricumhallii bacterial suspension dissolved in sterile water (1×10 9 CFU) by intragastric administration.
[0090] (2) Therapeutic trials
[0091] 9-week-old C57BL / 6J mice weighing 18-20g were punched with ear tags on the inside of the right ear of the mice and numbered in sequence; constant temperature and humidity, 12h light cycle, free food and water, regular replacement of bedding; normal feed was adaptively fed for 1 week to 10 weeks of age, and then treated according to the experimental groups. Each group of mice was gavaged regularly in the morning for 42 days (6 weeks), and then fed normally for 4 weeks. The functional structure of the mouse heart was detected by ultrasound; the body weight (BW) and tibia length (TL) of each group of mice were recorded after the mice were killed, and the mouse heart was removed and the heart weight (HW) was recorded; and the heart was stained with HE and Masson. The activity, coat color and death of the mice were observed every day, the mice were weighed regularly, and the food intake of the mice was recorded.
[0092] During the entire experimental period, the mice in each group had smooth fur and were in good mental state.
[0093] Effects of Anaerobutyricum hallii treatment on food intake and body weight in TAC-induced heart failure mice Figure 6 As shown, A is the change in food intake, and B is the change in body weight. The results showed that after oral administration of Anaerobutyricum hallii suspension, the food intake and body weight of mice in each group fluctuated slightly during the feeding period, but there was no significant change.
[0094] The experimental results of Anaerobutyricum hallii in treating cardiac hypertrophy are as follows Figure 7 As shown, A is the mouse heart morphology, B is the ratio of heart weight (HW) to body weight (BW), and C is the ratio of heart weight (HW) to tibia length (TL). The results showed that oral administration of Anaerobutyricum hallii suspension can reduce the heart-to-body ratio and heart-to-tibia ratio of mice, effectively control the size and weight of the heart, and reduce TAC-induced myocardial hypertrophy, indicating that Anaerobutyricum hallii can effectively treat TAC-induced cardiac hypertrophy.
[0095] (3) Mouse heart function and structure detection
[0096] The detection method is the same as the ultrasonic inspection described above in this embodiment.
[0097] Results of cardiac ejection fraction and fractional shortening in mice after treatment with Anaerobutyricum hallii Figure 8As shown, A is a representative image of mouse cardiac ultrasound, B is the left ventricular ejection fraction (LVEF) of mice, C is the left ventricular short axis shortening rate (LVFS) of mice, mean±SEM, ** indicates p<0.01; *** indicates p<0.001. The results showed that compared with the model group, the Anaerobutyricum hallii experimental group could effectively improve the TAC-induced cardiac ejection fraction and short axis shortening rate of mice, indicating that the Anaerobutyricum hallii bacterial suspension can effectively treat TAC-induced decreased cardiac function.
[0098] The results of left ventricular wall thickness and left ventricular volume in mice after treatment with Anaerobutyricum hallii are as follows Fig. 9 As shown, A is the left ventricular end-systolic anterior wall thickness of mice (LVAW; s), B is the left ventricular end-diastolic anterior wall thickness (LVAW; d), C is the left ventricular end-systolic posterior wall thickness (LVPW; s), D is the left ventricular end-diastolic posterior wall thickness (LVPW; d), E is the left ventricular end-systolic volume (LV vol; s), and F is the left ventricular end-diastolic volume (LV vol; d). The results showed that compared with the model group, the Anaerobutyricum hallii experimental group could effectively maintain the left ventricular wall thickness and left ventricular volume of TAC-induced mouse hearts, indicating that the Anaerobutyricum hallii bacterial suspension can effectively treat TAC-induced cardiac function decline.
[0099] (4) HE staining
[0100] The detection method is the same as the HE staining described above in this example.
[0101] The experimental results of Anaerobutyricum hallii improving myocardial hypertrophy and inflammatory cell infiltration are as follows Fig.10 As shown, A is a cross-sectional view of mouse heart, B is a representative view of HE staining of cardiomyocytes, and C is a representative view of inflammatory cell infiltration in cardiac tissue. The results showed that oral administration of Anaerobutyricum hallii suspension can inhibit cardiomyocyte hypertrophy, improve cardiac hypertrophy, inhibit myocardial hypertrophy, and significantly reduce the infiltration of inflammatory cells in myocardial tissue, indicating that Anaerobutyricum hallii suspension can effectively improve and treat TAC-induced cardiac hypertrophy, myocardial hypertrophy and inflammatory cell infiltration.
[0102] (5) Masson staining
[0103] The main steps are: baking at 55℃ for 30min→xylene for 2min, 3 times→100% alcohol for 1min→95% alcohol for 1min→70% alcohol for 1min→rinsing with running water for 10min→double distilled water for 1min→Weigert's iron hematoxylin staining for 5min→washing with tap water for 5min→removing residual liquid→1% hydrochloric acid alcohol differentiation for 4s→washing with tap water for 5min to return to blue→staining with Ponceau acid fuchsin solution for 10min→rinsing with distilled water for 5min→treating with phosphomolybdic acid aqueous solution for about 5min→re-staining with aniline blue solution for 5min→treating with 1% ice CH3COOH for 1min→70% alcohol once→90% alcohol once→100% alcohol for 30s, 3 times→xylene for 2min, 3 times→covering the slides with a coverslip while the xylene is still wet, taking pictures with a microscope; and calculating the percentage of collagen deposition area.
[0104] Effects of Anaerobutyricum hallii treatment on cardiac tissue and perivascular fibrosis Fig.11 As shown, A is the change of cardiac tissue fibrosis in mice, B is the change of perivascular fibrosis in mice, and C is the percentage of collagen deposition area (Collagen area / whole section). The results showed that oral administration of Anaerobutyricum hallii suspension can reduce the degree of myocardial fibrosis. This indicates that Anaerobutyricum hallii suspension can effectively improve and treat TAC-induced myocardial fibrosis.
[0105] In conclusion, Anaerobutyricum hallii can effectively improve and treat cardiac hypertrophy, decreased cardiac function, myocardial hypertrophy, inflammatory cell infiltration and myocardial fibrosis, and thus has an improving and therapeutic effect on ventricular remodeling and heart failure.
[0106] Example 3 Therapeutic effects of different bacteria on TAC-induced heart failure
[0107] 1. Isolation and cultivation of strains Anaerobutyricum hallii, Roseburia intestinalis, and Faecalibacterium prausnitzii
[0108] Anaerobutyricum hallii and Faecalibacterium prausnitzii were isolated from fecal samples of healthy donors and identified as the known strains Anaerobutyricum hallii DSM 3353 and Faecalibacterium prausnitzii DSM 17677. Roseburia intestinalis DSM14610 was introduced from DSM and purchased from Testo Biological, Ningbo, China.
[0109] DSMZ Medium 110 (minced meat medium) was used to culture Anaerobutyricum hallii, and modified fortified Clostridium medium was used to culture Faecalibacterium prausnitzii and Roseburia intestinalis. All the above bacteria were cultured anaerobically at 37°C. The bacteria were suspended under anaerobic conditions and the density was adjusted to 5×10 9 CFU / ml. The three strains after culture were separated and prepared into bacterial suspension using sterile water for subsequent experiments.
[0110] 2. Experimental Animals
[0111] The source of the experimental animals is the same as in Example 2.
[0112] In order to evaluate the therapeutic effect of Anaerobutyricum hallii, Roseburia intestinalis, and Faecalibacterium prausnitzii on TAC-induced heart failure, some mice were given a 6-week therapeutic gavage of bacterial suspension after TAC construction surgery. TAC construction was the same as in Example 2.
[0113] Experimental Grouping
[0114] ① Normal control group (Sham): 8 C57BL / 6J mice, each mouse was gavaged with 0.2 mL of sterile water every day;
[0115] ② Model control group (TAC): 10 C57BL / 6J mice. After TAC construction surgery, each mouse was gavaged with 0.2 mL of sterile water every day;
[0116] ③Anaerobutyricum hallii experimental group (TAC+Ah): 10 C57BL / 6J mice. After TAC construction surgery, each mouse was treated with 0.2 mL of 5×10 9CFU / mL of Anaerobutyricum hallii suspension dissolved in sterile water (1×10 9 CFU) by intragastric administration.
[0117] ④Roseburia intestinalis experimental group (TAC+Ri): 10 C57BL / 6J mice. After TAC construction surgery, each mouse was treated with 0.2 mL of 5×10 9 CFU / mL of Roseburia intestinalis suspension dissolved in sterile water (1×10 9 CFU) by intragastric administration.
[0118] ⑤Faecalibacterium prausnitzii experimental group (TAC+Fp): 10 C57BL / 6J mice. After TAC construction surgery, each mouse was inoculated with 0.2 mL of 5×10 9 CFU / mL of Faecalibacterium prausnitzii bacterial suspension dissolved in sterile water (1×10 9 CFU) by intragastric administration.
[0119] 9-week-old C57BL / 6J mice, weighing 18-20g, were numbered in sequence by punching ear tags on the inside of the right ear of the mice with a hole puncher; constant temperature and humidity, 12h light cycle, free food and water, regular replacement of bedding; ordinary feed was adaptively fed for 1 week to 10 weeks of age and then treated according to experimental groups. Each group of mice was gavaged regularly in the morning for 42 days (6 weeks), and then after normal feeding for 4 weeks, the mouse heart function structure was detected by ultrasound, and the detection method was the same as in Example 2.
[0120] The results of cardiac ejection fraction and short-axis shortening rate of mice after treatment with different bacteria are as follows Fig.12 As shown, A is the left ventricular ejection fraction (LVEF) of mice, B is the left ventricular fractional shortening (LVFS) of mice, mean±SEM, * indicates p<0.01, ** indicates p<0.01, *** indicates p<0.001. The results showed that compared with Roseburia intestinalis and Faecalibacteriumprausnitzii, the LVEF and LVFS values of the Anaerobutyricum hallii experimental group were significantly improved. Among the three strains, Anaerobutyricum hallii had the best effect on the treatment of TAC-induced cardiac function decline, indicating that Anaerobutyricum hallii has the best effect on improving cardiac function and has a better therapeutic effect on ventricular remodeling.
[0121] Example 4 Analysis of the effect of anaerobutyricum hallii metabolites on heart failure cell model
[0122] In order to determine whether the metabolites of Anaerobutyricum hallii also have a positive effect on the isoproterenol (ISO)-induced primary cardiomyocyte heart failure cell model, the present invention uses the metabolites of Anaerobutyricum hallii to act on the ISO-induced primary cardiomyocyte heart failure cell model, and simultaneously detects the expression levels of the heart failure marker atrial natriuretic peptide (ANP) and the myocardial hypertrophy marker β-MHC.
[0123] Preparation of sterile culture medium containing the metabolites of Anaerobutyricum hallii (Anaerobutyricum hallii metabolites, hallii medium): Add 1×10 8 CFU Anaerobutyricum hallii was cultured in 2 ml DSMZ Medium 110 culture medium for 48 hours, and the same volume of sterile DSMZ Medium 110 was used as a control culture medium (medium), followed by centrifugation (12000 rpm), and the supernatant was taken and filtered using a 0.22 um filter to obtain a sterile culture medium (hallii medium) containing the metabolites of Anaerobutyricum hallii.
[0124] The hearts of 3-day-old suckling mice were taken out and digested with trypsin and collagenase I to obtain primary cell suspension. After the auxiliary plate was left to stand for 1.5 hours, the suspended cell solution was recovered and plated again to obtain primary cardiomyocytes. On the second day, the control group 1 (Control) was added with cell culture medium (high glucose DMEM + 10% FBS); the model group (ISO) was added with 20μM isoproterenol (ISO), the control group 2 (ISO+medium) was added with 20μM ISO and 5% control culture medium (medium) by volume, and the experimental group (ISO+halliimedium) was added with 20μM ISO and 5% sterile culture medium containing metabolites of Anaerobutyricum hallii (hallii medium) by volume. After 48 hours of intervention in each group, cells were collected to extract proteins, and the expression levels of ANP and β-MHC were detected by western blotting.
[0125] The results of the effects of the metabolites of Anaerobutyricum hallii on the expression of markers of heart failure and cardiac hypertrophy in primary cardiomyocytes are as follows Fig.13As shown, A is a representative graph of β-MHC and ANP protein expression, B is a statistical graph of β-MHC relative expression, and C is a statistical graph of ANP relative expression. The results showed that the metabolites of Anaerobutyricum hallii can significantly downregulate and inhibit the expression levels of ANP and β-MHC proteins in primary cardiomyocytes. This indicates that the metabolites of Anaerobutyricum hallii can inhibit heart failure and myocardial hypertrophy, thereby inhibiting ventricular remodeling.
[0126] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. Use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating ventricular remodeling.
2. The use according to claim 1, characterized in that The anaerobutyric acid bacteria (Anaerobutyricum hallii) prevents and / or treats heart failure by preventing and / or treating ventricular remodeling.
3. The use according to claim 1, wherein the anaerobic butyric acid bacteria (Anaerobutyricum hallii) prevents and / or treats ventricular remodeling by inhibiting cardiac hypertrophy, decreased cardiac function, myocardial hypertrophy or myocardial fibrosis.
4. Use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating heart failure.
5. Use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating cardiac hypertrophy.
6. Use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating decreased cardiac function.
7. Use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating myocardial hypertrophy.
8. Use of anaerobutyricum hallii in the preparation of a medicament for preventing and / or treating myocardial fibrosis.
9. The use according to any one of claims 1 to 8, characterized in that: The anaerobutyricum hallii includes the bacterial cells of the anaerobutyricum hallii or the culture solution of the anaerobutyricum hallii.
